Comment from AstraZeneca

Summary: AstraZeneca Pharmaceuticals PLP submitted comments providing specific technical feedback and requests for clarification on the draft guidance for protocol deviations in clinical investigations. The company suggests refining definitions, clarifying reporting requirements for different types of deviations, and ensuring alignment with data privacy regulations and IRB procedures.